Oncology | Phase I Developments | UNITED KINGDOM

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan in Combination with TAGRISSO

Lead Product(s): Patritumab Deruxtecan,Osimertinib

Therapeutic Area: Oncology Product Name: U3-1402

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Daiichi Sankyo Co Ltd

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration August 06, 2020

Details:

The collaboration aims to evaluate the combination of patritumab deruxtecan (U3-1402) and TAGRISSO (osimertinib) in patients with EGFR-mutated advanced or metastatic non-small cell lung cancer (NSCLC).

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

AstraZeneca signs $6bn worth cancer asset deal with Daiichi Sankyo

Lead Product(s): DS-1062

Therapeutic Area: Oncology Product Name: DS-1062

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Daiichi Sankyo Co Ltd

Deal Size: $6,000.0 million Upfront Cash: $1,000.0 million

Deal Type: Agreement July 27, 2020

Details:

The Collaboration is Aimed at Developing and Commercialising DS-1062, Around the World, Except in Japan, Where Daiichi Sankyo Will Hold the Exclusive Rights to Manufacture and Supply DS-1062

Mereo BioPharma Group

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Mereo BioPharma Announces Completion of $70 Million Private Placement and Plans to Develop Etigilimab

Lead Product(s): Etigilimab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: OrbiMed

Deal Size: $70.0 million Upfront Cash: Undisclosed

Deal Type: Private Placement June 04, 2020

Details:

Along with this private placement, Mereo plans to advance etigilimab (Anti-TIGIT) into a Phase 1b study alongside progressing its rare disease product portfolio, based on the Company’s existing promising clinical data with etigilimab.

Mina Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

MiNA Therapeutics Presents Top Line Results from Phase Ib Study of MTL‑CEBPA in Combination with Sorafenib in Liver Cancer

Lead Product(s): MTL-CEBPA,Sorafenib

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 29, 2020

Details:

Observed clinical activity, including durable and complete tumour responses, suggests that MTL-CEBPA may increase the effectiveness of sorafenib standard of care.

Midatech Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Midatech Raises USD3 Million, Plans To Raise Further GBP1.8 Million

Lead Product(s): Panobinostat lactate

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: H.C. Wainwright

Deal Size: $3.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering May 18, 2020

Details:

The cash raised will be used to fund Midatech's MTX110 clinical programme, the development of an internal pipeline of Q-Sphera formulations for partnering, and for general corporate purposes.

Clinigen Group

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Clinigen Demonstrates IL-2 Plays Role in Emerging TIL Therapies

Lead Product(s): Interleukin,Tumor infiltrating lymphocyte,Nivolumab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 04, 2020

Details:

Study aimed at evaluating the safety and efficacy of TIL therapy in metastatic NSCLC (mNSCLC) after evidence of progression on nivolumab.

Epsilogen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Epsilogen Limited Announces Interim phase 1 MOv18 IgE data presented at AACR

Lead Product(s): MOv18 IgE

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 27, 2020

Details:

MOv18 IgE, at the doses administered, was found to be well tolerated in almost all patients, with urticaria1 being the most frequently observed adverse event.

Redx Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Redx Pharma Provides Update on Its Phase 1/2a Clinical Trial of RXC004

Lead Product(s): RXC004

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 23, 2020

Details:

Recruitment to Redx's phase 1/2a clinical trial of RXC004, an oral porcupine inhibitor, has been halted in line with the policy of the five recruiting hospital centres in the UK.

Kings College London

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

Epsilogen Licences Experimental Ige Antibody from KCL

Lead Product(s): MOv18 IgE

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Epsilogen

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement April 21, 2020

Details:

The antibody developed at KCL in collaboration with Cancer Research UK is the first therapeutic IgE antibody to enter clinical trials.

F-star Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Natural Products Expo

Participation Not Confirmed

Update your events

A Novel Mechanism of Action for FS118 and the Potential to Overcome PD-(L)1 Resistance Published in Clinical Cancer Research

Lead Product(s): FS118

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 16, 2020

Details:

Data highlighting the potential novel mechanism of action of its wholly-owned lead clinical asset FS118, a LAG-3/PD-L1-targeting tetravalent bispecific antibody.

Find

Find Oncology Drugs in Phase I Clinical Development in UNITED KINGDOM

United Kingdom

Product Type

Companies

AstraZeneca PLC

Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan in Combination with TAGRISSO

AstraZeneca PLC

AstraZeneca signs $6bn worth cancer asset deal with Daiichi Sankyo

Mereo BioPharma Group

Mereo BioPharma Announces Completion of $70 Million Private Placement and Plans to Develop Etigilimab

Mina Therapeutics

MiNA Therapeutics Presents Top Line Results from Phase Ib Study of MTL‑CEBPA in Combination with Sorafenib in Liver Cancer

Midatech Pharma

Midatech Raises USD3 Million, Plans To Raise Further GBP1.8 Million

Clinigen Group

Clinigen Demonstrates IL-2 Plays Role in Emerging TIL Therapies

Epsilogen

Epsilogen Limited Announces Interim phase 1 MOv18 IgE data presented at AACR

Redx Pharma

Redx Pharma Provides Update on Its Phase 1/2a Clinical Trial of RXC004

Kings College London

Epsilogen Licences Experimental Ige Antibody from KCL

F-star Therapeutics

A Novel Mechanism of Action for FS118 and the Potential to Overcome PD-(L)1 Resistance Published in Clinical Cancer Research